59504-75-5

Usage

Uses

Used in Organic Synthesis:
N-(bromoacetyl)methanesulfonamide is used as a reagent in organic synthesis for introducing the bromoacetyl functional group into organic compounds. Its high reactivity allows for the formation of various chemical bonds and the synthesis of a wide range of organic compounds.
Used in Industrial Water Treatment:
In the industrial water treatment industry, N-(bromoacetyl)methanesulfonamide is used as a biocide to control the growth of microorganisms and prevent biofouling in water systems. Its effectiveness in controlling microbial growth helps maintain the efficiency and longevity of water treatment systems.
Used in Research and Development:
Due to its unique chemical properties and reactivity, N-(bromoacetyl)methanesulfonamide is also used in research and development for the study of chemical reactions, synthesis of new compounds, and development of innovative applications in various fields.
It is important to handle N-(bromoacetyl)methanesulfonamide with care due to its potential toxicity and irritant properties. Proper safety measures, such as wearing protective gear and working in well-ventilated areas, should be taken to minimize exposure and ensure safe usage.

InChI:InChI=1/C3H6BrNO3S/c1-9(7,8)5-3(6)2-4/h2H2,1H3,(H,5,6)

Upstream product

• 3144-09-0 methanesulfonamide 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 1048660-96-3 2-(1-benzyl-2-isobutyl-1H-indol-4-yloxy)-N-(methylsulfonyl)acetamide 
• 1151654-71-5 C₅₀H₄₄F₆N₁₀O₇S 
• 475086-01-2 Selexipag 

Relevant academic research and scientific papers

Novel Aryl-Substituted Pyrimidones as Inhibitors of 3-Mercaptopyruvate Sulfurtransferase with Antiproliferative Efficacy in Colon Cancer

The enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) is one of the more recently identified mammalian sources of H2S. A recent study identified several novel 3-MST inhibitors with micromolar potency. Among those, (2-[(4-hydroxy-6-methylpyrimidin-2-yl)sulfanyl]-1-(naphthalen-1-yl)ethan-1-one) or HMPSNE was found to be the most potent and selective. We now took the central core of this compound and modified the pyrimidone and the arylketone sides independently. A 63-compound library was synthesized; compounds were tested for H2S generation from recombinant 3-MST in vitro. Active compounds were subsequently tested to elucidate their potency and selectivity. Computer modeling studies have delineated some of the key structural features necessary for binding to the 3-MST's active site. Six novel 3-MST inhibitors were tested in cell-based assays: they exerted inhibitory effects in murine MC38 and CT26 colon cancer cell proliferation; the antiproliferative effect of the compound with the highest potency and best cell-based activity (1b) was also confirmed on the growth of MC38 tumors in mice.

HERBICIDAL CINNOLINIUM COMPOUNDS

Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

CINNOLINIUM COMPOUNDS FOR USE IN A METHOD OF CONTROLLING UNWANTED PLANT GROWTH

The present invention relates to herbicidally active cinnolinium derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising such derivatives, as well as to the use of such compounds and compositions in controlling undesirable plant growth: in particular the use in controlling weeds, in crops of useful plants.

HERBICIDAL COMPOUNDS

Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.

PROSTACYCLIN RECEPTOR AGONIST

A compound represented by formula (I) or an isomer or a pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGI2 receptor.

Synthetic routes to treprostinil N-acyl methylsulfonamide

The synthesis of the prodrug candidate, treprostinil N-acyl methylsulfonamide 5 was accomplished from treprostinil 2 utilising protecting group strategies. A more direct synthesis for the prodrug was also achieved using a treprostinil triol precursor 12 and bromoacetyl acylmethylsulfonamide 14. The overall yield of treprostinil N-acyl sulfonamide 5 directly from the triol precursor 12 is similar to the protecting group strategies because deprotonation of the acidic proton in the bromoacetyl acylmethylsulfonamide 14 reduces electrophilicity. However, the more direct route using the treprostinil triol precursor holds greater promise as a strategy to prepare a wide range of treprostinil prodrug candidates. Treprostinil N-acyl methylsulfonamide prodrug 5 exhibited a 30-fold decrease in the potency at the human prostacyclin (IP) receptor compared to treprostinil 2 in an in vitro cyclic AMP assay.

CRYSTALLINE FORM VI OF SELEXIPAG

The present disclosure relates to solid state forms of Selexipag, processes for preparation thereof and pharmaceutical compositions thereof.

Selexipag intermediates and method for preparing selexipag

The invention belongs to the field of chemical preparation, and relates to selexipag intermediates and a method for preparing selexipag. The selexipag intermediates are a compound SLP-4, a compound SLP-7, a compound SLP-8 and a compound SLP-10. The selexipag intermediates and the method have the advantages that the method for preparing the selexipag includes reasonable routes and is low in cost and operative difficulty and little in environmental pollution, raw materials are easily available, accordingly, requirements of large-scale industrial production can be met by the method, and the like.

SOLID STATE FORMS OF SELEXIPAG

The present disclosure relates to solid state forms of Selexipag, in particular selexipag forms IV and V, and processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

PROCESSES FOR PREPARATION OF SELEXIPAG AND ITS AMORPHOUS FORM

The present application relates to processes for preparation of Selexipag, its amorphous form, amorphous solid dispersion and pharmaceutical composition thereof. Formula (I):